Celcuity Inc. (CELC)

NASDAQ: CELC · Real-Time Price · USD
10.53
+0.35 (3.44%)
May 8, 2025, 4:00 PM EDT - Market closed
3.44%
Market Cap 398.45M
Revenue (ttm) n/a
Net Income (ttm) -111.78M
Shares Out 37.84M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 240,888
Open 10.20
Previous Close 10.18
Day's Range 10.20 - 10.70
52-Week Range 7.58 - 19.77
Beta 0.56
Analysts Strong Buy
Price Target 30.17 (+186.52%)
Earnings Date May 14, 2025

About CELC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 87
Stock Exchange NASDAQ
Ticker Symbol CELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price forecast is $30.17, which is an increase of 186.52% from the latest price.

Price Target
$30.17
(186.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

1 day ago - GlobeNewsWire

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian...

5 weeks ago - GlobeNewsWire

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Apoorva Chaloori - ICR Healthcare, Investor Relations Brian Sullivan - Co-Founder & Chief E...

5 weeks ago - Seeking Alpha

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial ...

5 weeks ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi...

6 weeks ago - GlobeNewsWire

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian ...

2 months ago - GlobeNewsWire

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash posi...

2 months ago - Seeking Alpha

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months

5 months ago - GlobeNewsWire

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Apoorva Chaloori - ICR Westwicke, Investor Relations Brian Sullivan - Co-Founder & Chief...

6 months ago - Seeking Alpha

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial r...

6 months ago - GlobeNewsWire

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian ...

6 months ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil...

6 months ago - GlobeNewsWire

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC) Q2 2024 Earnings Conference Call August 14, 2024 4:30 AM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief...

9 months ago - Seeking Alpha

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial r...

9 months ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil...

9 months ago - GlobeNewsWire

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorab...

11 months ago - Seeking Alpha

Celcuity To Participate in Jefferies Global Healthcare Conference

MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partici...

1 year ago - GlobeNewsWire

Celcuity Announces Pricing of Underwritten Common Stock Offering

MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing ...

1 year ago - GlobeNewsWire

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it plan...

1 year ago - GlobeNewsWire

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Fi...

1 year ago - Seeking Alpha

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial re...

1 year ago - GlobeNewsWire

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

1 year ago - GlobeNewsWire

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial ...

1 year ago - GlobeNewsWire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi...

1 year ago - GlobeNewsWire